Aaron B. Mendelsohn, PhD, MPH, is a Research Scientist III in the Department of Population Medicine (DPM) at Harvard Medical School and Harvard Pilgrim Health Care Institute. He is an epidemiologist specializing in pharmacoepidemiology with interest areas in pharmaceutical risk management, disease and drug-based registries, infectious disease epidemiology, patient preferences and patient-reported outcomes, and epidemiological methods. His current research activities involve evaluating safety and effectiveness outcomes, and utilization patterns, for medicinal products using claims data collected through real world healthcare delivery in distributed data networks.
Aaron earned his doctorate in Epidemiology from the University of Pittsburgh. He received post-doctoral training in applied epidemiology through the Centers for Disease Control and Prevention’s Epidemic Intelligence Service (EIS) where he was assigned to the U.S. Food and Drug Administration (FDA) with the primary responsibility of conducting active surveillance for adverse drug events through a representative network of emergency departments in the United States. His work at the FDA earned him the Agency’s Outstanding Service Award as part of the NSAID Scientific Review Team. Prior to joining the Therapeutics Research and Infectious Disease Epidemiology (TIDE) team within DPM, Aaron headed the drug safety epidemiology and product risk management units for two biotechnology companies, as well as spending several years consulting for a variety of pharmaceutical clients. He has delivered numerous webinars and training courses to regulators and international audiences on benefit-risk evaluation of medicinal products.